Skip to main content
TipRanks
Go Ultimate75% OFF

Staar Surgical (STAA) AI Stock Analysis

573 Followers
STAA

Staar Surgical

(NASDAQ:STAA)

Select Model
Rating:58Neutral
Price Target:$25.00â–¼(-2.19% Downside)
Action:reiterated
Date:11/05/26

The score is held back mainly by weakened and volatile profitability/cash-flow history (despite a strong, low-leverage balance sheet) and an extremely high P/E with no dividend support. Offsetting factors include constructive technical momentum and a positive earnings-call tone highlighting improving margins, cost discipline, and pipeline progress, though supply constraints and limited forward guidance remain meaningful near-term risks.

Positive Factors
Structural ICL AdoptionThe shift from laser procedures toward lens-based correction supports a durable industry growth opportunity for STAAR’s ICL platform. If adoption continues across multiple markets, the company can expand procedure volumes, surgeon utilization, and its competitive position over the next several quarters.
Negative Factors
Profitability DeteriorationThe multi-year deterioration from strong profitability to losses and near break-even TTM earnings raises questions about operating leverage and the durability of earnings recovery. Strong gross margins have not consistently translated into bottom-line profits, limiting internal funding capacity.

Staar Surgical Key Performance Indicators (KPIs)

Revenue by GeographyBreaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.

$0.00$25.00M$50.00M$75.00M$100.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Foreign sales overwhelmingly drive Staar’s top line but are highly lumpy—big quarter-to-quarter swings point to timing of large international orders or distributor restocking rather than steady end-market demand. Domestic revenue is small but steadily creeping higher, signaling limited U.S. penetration and low diversification benefit. For investors this means headline revenue and margins will be volatile until management smooths international channel timing or grows domestic share; focus on order backlog, distributor contracts and reimbursement/approval updates for true momentum clarity.

Data provided by:The Fly

Staar Surgical (STAA) vs. SPDR S&P 500 ETF (SPY)

-50%-40%-30%-20%-10%0%10%20%30%STAA-6.54%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.28B
Dividend Yield
―
Average Volume (3M)
850.67K
Price to Earnings (P/E)
2542.4
Beta (1Y)
1.05
Revenue Growth
42.36%
EPS Growth
―
Country
US
Employees
921
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

Staar Surgical Business Overview & Revenue Model

Company Description

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated del...

How the Company Makes Money

STAAR Surgical makes money primarily by selling implantable lenses and related ophthalmic products to eye-care customers through a combination of direct sales and distribution partners, depending on the geography. The company’s principal revenue stre...

Staar Surgical Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:-5.93%|Next Earnings Date:Feb 24, 2027
Earnings Call SentimentPositive

The call was broadly positive. Management reported record nine-month revenue, strong cash generation, GAAP profitability, growth across China and most international regions, expanding EVO+ and toric adoption, new manufacturing capacity, and progress toward presbyopia trials. The main negatives were lower reported third-quarter revenue and profitability versus the prior-year comparison, reduced gross margin from stated temporary pressures, supply constraints, regional weakness in Japan and South Korea, and limited forward guidance. Highlights significantly outweighed the lowlights.

Positive Updates

Record Nine-Month Revenue and Profitability
STAAR delivered record revenue through the first 9 months, generated GAAP net income and free cash flow, and remained debt-free. Management said the performance supports expectations for strong full-year GAAP net income and free cash flow.

Negative Updates

Reported Third-Quarter Revenue Decline Against Prior-Year Comparison
Third-quarter net sales were $83.4 million, down 12% from the prior-year quarter because the prior-year period included $25.9 million of deferred China sales. China reported net sales of $39.3 million versus $55.8 million in the prior-year quarter on that reported basis.

Company Guidance

Management expects fourth quarter gross margin to be above the third quarter and gross margin to continue to improve in 2027, remains on track to meet the $225 million adjusted operating expense target, and expects strong full year GAAP net income and free cash flow; in China, Q4 would be lower from a shape of demand standpoint, yet the company expects to grow versus last year, while stopping short of giving guidance or saying when it might be willing to give guidance for 2027. Each percentage point of yield improvement could generate approximately $750,000 to $1 million in annual incremental gross profit, and first-in-human trials for 2 Collamer-based presbyopia products are expected to begin patient enrollment in the next few months, subject to the receipt of the remaining required regulatory authorizations.

Staar Surgical Financial Statement Overview

Summary

Financials are mixed. The balance sheet is a clear strength with low leverage (debt-to-equity ~0.09) and ample flexibility (Balance Sheet Score 76). However, profitability has deteriorated versus prior years with multi-year losses and only near break-even TTM results (Income Statement Score 44). Cash flow is improving in TTM (positive operating and free cash flow), but remains volatile across years (Cash Flow Score 52).

Income Statement

44Neutral

Balance Sheet

76Positive

Cash Flow

52Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue328.27M239.44M313.90M322.42M284.39M230.47M
Gross Profit240.13M182.42M239.58M252.65M223.38M178.64M
EBITDA17.02M-73.94M-2.16M38.82M50.06M34.98M
Net Income530.00K-80.45M-20.21M21.35M39.66M27.51M
Balance Sheet
Total Assets485.16M451.68M509.52M488.69M418.82M345.78M
Cash, Cash Equivalents and Short-Term Investments206.41M187.54M230.49M220.73M211.64M199.71M
Total Debt33.64M38.35M38.74M35.83M31.04M32.06M
Total Liabilities109.03M107.49M112.19M102.74M82.71M87.22M
Stockholders Equity376.13M344.18M397.33M385.95M336.11M258.56M
Cash Flow
Free Cash Flow17.85M-40.05M-7.67M-3.59M17.61M30.32M
Operating Cash Flow21.40M-34.23M15.72M14.59M35.72M43.96M
Investing Cash Flow-59.30M46.34M-59.22M74.35M-156.38M-13.64M
Financing Cash Flow-4.56M-4.55M5.72M7.42M8.30M17.79M

Staar Surgical Technical Analysis

Technical Analysis SentimentPositive
Last Price25.56

Price Trends

50DMA23.05Positive
100DMA24.01Positive
200DMA23.97Positive

Market Momentum

MACD0.89Negative
RSI55.37Neutral
STOCH43.22Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STAA, the sentiment is Positive. The current price of 25.56 is above the 20-day moving average (MA) of 24.88, above the 50-day MA of 23.05, and above the 200-day MA of 23.97, indicating a bullish trend. The MACD of 0.89 indicates Negative momentum. The RSI at 55.37 is Neutral, neither overbought nor oversold. The STOCH value of 43.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STAA.

Staar Surgical Risk Analysis

Staar Surgical disclosed 41 risk factors in its most recent earnings report. Staar Surgical reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.The completion of the Merger is subject to certain closing conditions, including stockholder approval and certain regulatory conditions, which may not be satisfied on a timely basis or at all, and the failure to consummate the Merger within the expected timeframe or at all could adversely impact our business, financial condition, and results of operations.Q2, 2025
2.The announcement and pendency of our proposed acquisition by Alcon could adversely impact our business, financial condition, and results of operations.Q2, 2025
3.Lawsuits may be filed against us or our directors or officers challenging the transactions contemplated by the Merger Agreement or the Merger, which could prevent or delay the completion of the Merger or result in the payment of damages.Q2, 2025

Staar Surgical Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

STAA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
BLCOBLCO65Neutral$7.45B-67.36-1.73%―8.88%63.73%
STAASTAA58Neutral$1.28B2542.430.15%―42.36%―
COOCOO57Neutral$11.55B20.786.88%―4.73%43.89%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%STAACOOBLCODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
STAA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
STAAStaar Surgical Company25.56-0.89-3.36%
COOCooper Companies60.72-11.43-15.84%
BLCOBausch + Lomb Corporation20.836.2142.48%

Staar Surgical Corporate Events

Business Operations and StrategyExecutive/Board ChangesStock BuybackFinancial Disclosures

STAAR Surgical Reports Third-Quarter 2026 Financial Results

Positive
Nov 4, 2026

STAAR Surgical reported third-quarter 2026 results for the period ended October 2, 2026, with net sales of $83.4 million, net income of $5.6 million and adjusted EBITDA of $14.4 million. For the first nine months, revenue reached a record $270.5 mill...

Business Operations and StrategyExecutive/Board Changes

Staar Surgical Reappoints David Bailey to Drive Growth

Positive
Sep 10, 2026

On September 8, 2026, STAAR Surgical appointed former Chief Executive Officer David Bailey as Chief Commercial Officer, returning him to the company’s executive committee with responsibility for driving revenue growth and commercial strategy. Bailey,...

Business Operations and StrategyFinancial Disclosures

Staar Surgical posts strong Q2 growth and profits

Positive
Aug 12, 2026

STAAR Surgical reported strong financial performance for the second quarter ended July 3, 2026, highlighted by net sales of $93.5 million, up 111% year over year, and a swing to net income of $8.1 million from a loss a year earlier. Adjusted EBITDA r...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026